November–December 2024

Summary Comments

• Most frequently detected viruses across all age groups during December:
  • Rhino/Enterovirus: 19.7%
  • SARS-CoV-2: 17.7%
• Epidemiological Week 1–52:
  • SARS-CoV-2: Increased from 7% (week 44) to 23.4% (week 52)
    • Highest rates:
      • Eastern Cape: 23.6%
      • Kwa-Zulu Natal: 22.7%
      • Western Cape: 19.6%
      • Mpumalanga: 15.1%
      • Gauteng: 13.6%
  • Influenza A & B: Stable; 3.1% for influenza A and 0% for influenza B during week 52
  • RSV: Low at 0.6% in week 52

Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups

November 2024:

• Rhino/Enterovirus: 28.1%
• Rhinovirus: 21.7%
• Parainfluenza 1–4: 8.7%
• SARS-CoV-2: 13.9%
• Influenza A: 1.9%
• Influenza B: 2.9%
• RSV: 5.5%
• Adenovirus: 2.4%
• Metapneumovirus: 7.5%

December 2024:

• Rhino/Enterovirus: 19.7%
• Rhinovirus: 14.4%
• Parainfluenza 1–4: 5.4%
• SARS-CoV-2: 17.7%
• Influenza A: 3.1%
• Influenza B: 0%
• RSV: 0.6%
• Adenovirus: 2.9%
• Metapneumovirus: 5.3%

Atypical Bacterial Pathogens (Weeks 1–52)

Detected Cases per Pathogen (illustrative by week):

• B. pertussis
• M. pneumoniae
• C. pneumoniae

No cases of Legionella pneumophila in December.

Age Distribution:

Bordetella pertussis:

• 0–6 months: 17%
• 6–12 months: 7%
• 1–5 years: 27%
• 6–12 years: 21%
• 13–18 years: 4%
• 19–64 years: 17%

65 years: 7%

Mycoplasma pneumoniae:

• 0–6 months: 2%
• 6–12 months: 5%
• 1–5 years: 27%
• 6–12 years: 28%
• 13–18 years: 8%
• 19–64 years: 26%

65 years: 4%

Chlamydia pneumoniae:

• 0–6 months: 1%
• 6–12 months: 3%
• 1–5 years: 45%
• 6–12 years: 27%
• 13–18 years: 4%
• 19–64 years: 14%

65 years: 2%

Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)

<1 Year Age Group

November 2024:

• Rhino/Enterovirus: 41.3%
• Rhinovirus: 33.8%
• SARS-CoV-2: 10%
• Parainfluenza 1–4: 4.6%
• Adenovirus: 10.4%
• Metapneumovirus: 7.7%
• Influenza A: 0.3%
• Influenza B: 0.2%

December 2024:

• Rhino/Enterovirus: 33.8%
• Rhinovirus: 21.8%
• SARS-CoV-2: 17.7%
• Parainfluenza 1–4: 3.7%
• Adenovirus: 10%
• Metapneumovirus: 4.9%
• Influenza A: 0.2%
• Influenza B: 0.7%

1–5 Year Age Group

November 2024:

• Rhino/Enterovirus: 51.6%
• Rhinovirus: 35.8%
• SARS-CoV-2: 4.1%
• Parainfluenza 1–4: 4.3%
• Adenovirus: 9.8%
• Enterovirus: 18.3%
• Metapneumovirus: 6.1%
• Influenza A: 2.7%
• Influenza B: 0.3%

December 2024:

• Rhino/Enterovirus: 44.8%
• Rhinovirus: 32.7%
• SARS-CoV-2: 10.7%
• Parainfluenza 1–4: 3.4%
• Adenovirus: 16.4%
• Enterovirus: 18.3%
• Metapneumovirus: 6.1%
• Influenza A: 2.7%
• Influenza B: 0.3%

6–12 Year Age Group

November 2024:

• Rhino/Enterovirus: 42.8%
• Rhinovirus: 37.7%
• SARS-CoV-2: 7.8%
• Parainfluenza 1–4: 4.1%
• Adenovirus: 4.7%
• Influenza A: 2.6%
• Influenza B: 1%
• RSV: 0%

December 2024:

• Rhino/Enterovirus: 21.9%
• Rhinovirus: 15.5%
• SARS-CoV-2: 8.1%
• Parainfluenza 1–4: 2.0%
• Adenovirus: 2.2%
• Influenza A: 2.4%
• Influenza B: 0%
• RSV: 0.8%